Endovia Health Sciences (EDVA) Revenue Growth (1y) (2013 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Revenue Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 2.11% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 29.63% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 66.86% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 16.50% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 296.11% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -93.84% |
| Dec 31, 2025 | 86.81% |
| Sep 30, 2025 | -59.97% |
| Jun 30, 2025 | -102.24% |
| Mar 31, 2025 | -95.55% |
| Dec 31, 2024 | -202.96% |
| Sep 30, 2024 | -80.91% |
| Jun 30, 2024 | -79.85% |
| Mar 31, 2024 | -73.54% |
| Dec 31, 2023 | -43.89% |
| Sep 30, 2023 | 5.62% |
| Jun 30, 2023 | 15.47% |
| Mar 31, 2023 | 48.29% |
| Dec 31, 2022 | 74.74% |
| Sep 30, 2022 | 65.09% |
| Jun 30, 2022 | 30.96% |
| Mar 31, 2022 | 79.25% |
| Dec 31, 2021 | 153.33% |
| Sep 30, 2021 | 325.73% |
| Jun 30, 2021 | 732.37% |